Creative Medical Technology Holdings (CELZ)

Executive Summary

Creative Medical Technology Holdings is a private regenerative medicine company focused on advancing stem cell-based therapies for immunology, endocrinology, urogynecology, and orthopedics. The company's platforms include supercharged autologous immunotherapy and rapid autologous stem cell therapies, aiming to address significant unmet medical needs. Leveraging a disruptive approach, Creative Medical seeks to improve patient outcomes through cell therapies that harness the body's own regenerative capabilities. The company is headquartered in Phoenix, Arizona, and operates as a clinical-stage entity with a focus on proof-of-concept and early-stage trials. While Creative Medical has yet to achieve regulatory approvals or commercial sales, it is advancing multiple preclinical and clinical programs. The company's strategy revolves around validating its core technology platforms through clinical data and potential partnerships. Given the early stage of development, the company faces typical risks such as funding requirements, regulatory hurdles, and competition. However, if successful, its platforms could offer differentiated treatments for chronic and acute conditions, positioning the company for significant long-term value creation.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 Trial for Lead Stem Cell Therapy Candidate30% success
• Q1 2027Announcement of Strategic Partnership or Licensing Deal25% success
• Q3 2026Preclinical Data Release for Immunotherapy Platform40% success